Sieto Bosgra
Overview
Explore the profile of Sieto Bosgra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
376
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katai C, Smithline S, Thalhauser C, Bosgra S, Elassaiss-Schaap J
J Pharmacokinet Pharmacodyn
. 2024 Jun;
51(6):759-783.
PMID: 38914910
A basic FcRn-regulated clearance mechanism is investigated using the method of matched asymptotic expansions. The broader aim of the work is to obtain further insight on the mechanism, thereby providing...
2.
Berman C, Antonsson M, Batkai S, Bosgra S, Chopda G, Driessen W, et al.
Nucleic Acid Ther
. 2023 Aug;
33(5):287-305.
PMID: 37590469
This white paper summarizes the recommendations of the absorption, distribution, metabolism, and excretion (ADME) Subcommittee of the Oligonucleotide Safety Working Group for the characterization of absorption, distribution, metabolism, and excretion...
3.
Hiemstra I, Santegoets K, Janmaat M, De Goeij B, Ten Hagen W, van Dooremalen S, et al.
EBioMedicine
. 2023 Jun;
93:104663.
PMID: 37379657
Background: HexaBody®-CD38 (GEN3014) is a hexamerization-enhanced human IgG1 that binds CD38 with high affinity. The E430G mutation in its Fc domain facilitates the natural process of antibody hexamer formation upon...
4.
van Deutekom J, Beekman C, Bijl S, Bosgra S, van den Eijnde R, Franken D, et al.
Nucleic Acid Ther
. 2023 Apr;
33(3):193-208.
PMID: 37036788
In the last two decades, antisense oligonucleotides (AONs) that induce corrective exon skipping have matured as promising therapies aimed at tackling the dystrophin deficiency that underlies the severe and progressive...
5.
Bosgra S, Sipkens J, de Kimpe S, den Besten C, Datson N, van Deutekom J
Nucleic Acid Ther
. 2019 Aug;
29(6):305-322.
PMID: 31429628
Delivery to the target site and adversities related to off-target exposure have made the road to clinical success and approval of antisense oligonucleotide (AON) therapies challenging. Various classes of AONs...
6.
Kourkouta E, Weij R, Gonzalez-Barriga A, Mulder M, Verheul R, Bosgra S, et al.
Mol Ther Nucleic Acids
. 2019 Aug;
17:601-614.
PMID: 31394429
Spinocerebellar ataxia type 3 (SCA3) and type 1 (SCA1) are dominantly inherited neurodegenerative disorders that are currently incurable. Both diseases are caused by a CAG-repeat expansion in exon 10 of...
7.
van Putten M, Tanganyika-de Winter C, Bosgra S, Aartsma-Rus A
Nucleic Acid Ther
. 2019 Jan;
29(2):92-103.
PMID: 30672725
Duchenne muscular dystrophy is a severe, progressive muscle-wasting disease that is caused by mutations that abolish the production of functional dystrophin protein. The exon skipping approach aims to restore the...
8.
de Ligt R, van Duijn E, Grossouw D, Bosgra S, Burggraaf J, Windhorst A, et al.
Clin Transl Sci
. 2018 Jul;
11(6):573-581.
PMID: 30052317
A clinical pharmacokinetic study was performed in 12 healthy women to evaluate systemic exposure to aluminum following topical application of a representative antiperspirant formulation under real-life use conditions. A simple...
9.
Colaianna M, Ilmjarv S, Peterson H, Kern I, Julien S, Baquie M, et al.
Arch Toxicol
. 2016 Mar;
91(1):365-391.
PMID: 27015953
Identification of neurotoxic drugs and environmental chemicals is an important challenge. However, only few tools to address this topic are available. The aim of this study was to develop a...
10.
Bosgra S, Vlaming M, Vaes W
Clin Pharmacokinet
. 2015 Aug;
55(1):1-15.
PMID: 26242381
Microdosing studies allow clinical investigation of pharmacokinetics earlier in drug development, before all high-dose safety concerns have been sorted out. Furthermore, microdosing allows inclusion of target groups that are inadmissible...